ApoE-modified solid lipid nanoparticles: A feasible strategy to cross the blood-brain barrier

作者：Dal Magro R^*; Ornaghi F; Cambianica I; Beretta S; Re F; Musicanti C; Rigolio R; Donzelli E; Canta A; Ballarini E; Cavaletti G; Gasco P; Sancini G

来源：Journal of Controlled Release, 2017, 249: 103-110.

DOI：10.1016/j.jconrel.2017.01.039

• Solid lipid nanoparticles
• ApoE-derived peptide
• Pulmonary administration
• Brain targeting
• Blood-brain barrier

Solid lipid nanoparticles (SLN) are colloidal drug delivery systems characterized by higher entrapment efficiency, good scalability of the preparation process and increased sustained prolonged release of the payload compared to other nanocarriers. The possibility to functionalize the surface of SLN with ligands to achieve a site specific targeting makes them attractive to overcome the limited blood-brain barrier (BBB) penetration of therapeutic compounds. SLN are prepared for brain targeting by exploiting the adaptability of warm microemulsion process for the covalent surface modification with an Apolipoprotein E-derived peptide (SLN-mApoE). Furthermore, the influence of the administration route on SLN-mApoE brain bioavailability is here evaluated. SLN-mApoE are able to cross intact a BBB in vitro model. The pulmonary administration of SLN-mApoE is related to a higher confinement in the brain of Balb/c mice compared to the intravenous and intraperitoneal administration routes, without inducing any acute inflammatory reaction in the lungs. These results promote the pulmonary administration of brain-targeted SLN as a feasible strategy for improving brain delivery of therapeutics.

• 出版日期2017-3-10